Core Viewpoint - Perspective Therapeutics, Inc. is advancing its radiopharmaceutical treatments for cancer, with significant presentations at the SNMMI 2025 Annual Meeting highlighting its clinical trials and novel imaging agents [1][2][3][4]. Group 1: Clinical Trials and Presentations - The company is presenting findings on [Pb]VMT-α-NET, an imaging agent in a Phase 1/2a clinical trial for patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors, indicating it was well-tolerated among patients [3][5]. - A second presentation focuses on [Ga]PSV377, a novel PET imaging agent targeting fibroblast activation protein, which showed strong affinity and tumor retention in preclinical models, with promising first-in-human imaging results [4][8]. - Both presentations are scheduled for the SNMMI 2025 Annual Meeting, with poster sessions on June 21 and oral sessions on June 23 [2]. Group 2: Product Development and Technology - Perspective Therapeutics is utilizing a proprietary technology that employs the alpha-emitting isotope Pb to deliver targeted radiation to cancer cells, enhancing treatment efficacy while minimizing toxicity [9][10]. - The company is conducting multi-center, open-label studies for its products, including [Pb]VMT-α-NET and PSV359, aimed at improving patient outcomes through personalized treatment approaches [5][8][10]. - The company is expanding its regional network of drug product candidate finishing facilities to support clinical trials and commercial operations [10].

[212Pb]VMT-α-NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) than the dose administered to patients in Cohort 2Dosimetry sub-study analysis presented at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2025 Annual Meeting to advance utility of dosimetry in clinical development when considered with clinical dataOn track to submit further clinical updates to scientific congresses in 2H 2025, including longer safety follow-up on all pat ...

Core Viewpoint - Perspective Therapeutics, Inc. announced updated interim results from its ongoing Phase 1/2a clinical trial of [Pb]VMT-α-NET, presented at the 2025 ASCO Annual Meeting, indicating a favorable safety profile and promising anti-tumor activity in patients with neuroendocrine tumors [1][5][11]. Clinical Trial Overview - The Phase 1/2a clinical trial is a multi-center, open-label study focusing on patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors who have not received prior radiopharmaceutical therapy [2][12]. - Cohort 2 was reopened for enrollment in August 2024, with a total of 33 additional patients enrolled by April 30, 2025 [4][12]. Efficacy and Safety Data - Updated interim efficacy data were presented for two patients in Cohort 1 and seven patients in Cohort 2, with a data cut-off date of April 30, 2025 [3][5]. - Among 42 patients who received at least one treatment, there were no dose-limiting toxicities (DLTs) or treatment discontinuations due to adverse events reported [4][5]. - Ten patients experienced at least one Grade 3 treatment emergent adverse event (TEAE), with the majority deemed unrelated to [Pb]VMT-α-NET [4][5]. Anti-Tumor Activity - Four of seven patients in Cohort 2 experienced investigator-assessed objective responses, with three confirmed responses [5][11]. - Seven out of nine patients in Cohorts 1 and 2 remained free from disease progression after more than one year of follow-up [5][11]. Future Plans and Regulatory Engagement - The company plans to submit longer safety follow-up data and preliminary efficacy data for a subgroup for presentation at a scientific congress in the second half of 2025 [11][12]. - The company is engaging with the FDA to continue pursuing dose finding for [Pb]VMT-α-NET [10][11]. Company Background - Perspective Therapeutics, Inc. specializes in developing advanced radiopharmaceutical treatments for cancers, utilizing proprietary technology to deliver targeted radiation to cancer cells [14][15]. - The company is also developing complementary imaging diagnostics to personalize treatment and optimize patient outcomes [14].

First of several clinical updates through mid-2026 accepted for presentation at the 2025 American Society of Clinical Oncology Annual Meeting, with recruitment progressing for all three of our clinical stage potential new medicines based on our next generation targeted radiopharmaceutical technology platformEnrollment ongoing for VMT-α-NET, a next generation SSTR2-targeting potential new medicine, with 40 patients enrolled through end of April 2025 in Cohort 2 of the Phase 1/2a trial in neuroendocrine tumor ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File Number: 001-33407 PERSPECTIVE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) | De ...

[Business Highlights and Q1 2025 Results](index=1&type=section&id=Perspective%20Therapeutics%20Provides%20Recent%20Business%20Highlights%20and%20Reports%201Q%202025%20Results) [Recent Business Highlights](index=1&type=section&id=Recent%20Business%20Highlights) The company advanced its clinical trials and U.S. manufacturing, supported by a strong cash position of $212 million - Enrollment is ongoing for the VMT-α-NET Phase 1/2a trial in neuroendocrine tumors, with **40 patients enrolled** in Cohort 2 as of the end of April 2025[3](index=3&type=chunk) - The VMT01 trial for melanoma saw the first patient treated at a new monotherapy dose level in April 2025 and the first patient treated in combination with nivolumab in March 2025[3](index=3&type=chunk) - Achieved **first-in-human dosing of PSV359**, a therapy targeting FAP-α, which is associated with multiple prevalent solid tumors[3](index=3&type=chunk) - The company is expanding U.S. manufacturing to meet clinical and future commercial demand for its radiopharmaceutical products[3](index=3&type=chunk) - As of March 31, 2025, cash, cash equivalents, and short-term investments were approximately **$212 million**, providing a cash runway into late 2026[3](index=3&type=chunk) [Program Highlights](index=2&type=section&id=Program%20Highlights) [VMT-α-NET for Neuroendocrine Tumors (NETs)](index=2&type=section&id=VMT-%CE%B1-NET) The VMT-α-NET trial shows promising anti-tumor activity and a favorable safety profile in NET patients - The trial is a multi-center, open-label study (NCT05636618) for patients with unresectable or metastatic SSTR2-positive NETs who have not received prior radiopharmaceutical therapies, and the program has received **FDA Fast Track Designation**[5](index=5&type=chunk) - As of April 30, 2025, a total of **40 patients** have begun treatment in Cohort 2 (5.0 mCi dose)[10](index=10&type=chunk) - Safety findings as of January 10, 2025, showed **no dose-limiting toxicities (DLTs)**, no grade 4 or 5 treatment-emergent adverse events (TEAEs), and no treatment discontinuations due to AEs[10](index=10&type=chunk) - As of January 10, 2025, anti-tumor activity in Cohort 2 (7 patients) included **one confirmed response and two unconfirmed responses**, while eight of nine total patients remained on study without progressive disease[10](index=10&type=chunk) - Updated data on [212Pb]VMT-α-NET has been accepted for an oral presentation at the **2025 ASCO Annual Meeting** on May 30, 2025[10](index=10&type=chunk) [VMT01 for Melanoma](index=3&type=section&id=VMT01) The VMT01 program is exploring a lower dose level for melanoma following favorable initial safety data - The trial (NCT05655312) is evaluating VMT01 in previously treated patients with **MC1R-positive melanoma**[11](index=11&type=chunk) - The Safety Monitoring Committee (SMC) recommended exploring a **lower dose of 1.5 mCi**, both as monotherapy and in combination with nivolumab, with the first patients in these new cohorts treated in March and April 2025[13](index=13&type=chunk) - As of September 4, 2024, data from higher dose cohorts (3.0 mCi and 5.0 mCi) showed **no DLTs** or treatment-related discontinuations, with TEAEs being mostly Grade 1 and 2[14](index=14&type=chunk) - In the higher dose cohorts, one patient experienced an **unconfirmed objective response**, and two had stable disease, supporting the exploration of lower radiation doses[14](index=14&type=chunk) [PSV359 for Solid Tumors](index=5&type=section&id=PSV359) The novel radiopharmaceutical PSV359 entered clinical-stage development with the first patient dosed in April 2025 - PSV359 targets **FAP-α**, which is expressed in multiple highly prevalent solid tumors with unmet medical needs[16](index=16&type=chunk) - The **first patient was treated** with [212Pb]PSV359 in April 2025, and activation activities are underway for additional clinical sites[17](index=17&type=chunk) [Manufacturing, Supply Chain, and IP](index=5&type=section&id=Other%20Business%20Highlights) [Manufacturing and Supply Chain](index=5&type=section&id=Manufacturing%20and%20Supply%20Chain) The company is expanding its U.S. manufacturing network and has secured its key isotope supply through 2026 - The company has two operational U.S. manufacturing sites and is building out **three additional facilities** in the Houston, Chicago, and Los Angeles metropolitan areas[20](index=20&type=chunk)[25](index=25&type=chunk) - The company is expanding capacity at its Somerset, NJ facility, which began shipping 212Pb-labeled radiopharmaceuticals in **Q4 2024**[25](index=25&type=chunk) - The company procures the key starting material, 228Th, from the U.S. Department of Energy (DOE) and entered a new purchase order in May 2025 to **secure supply for 2025 and 2026**[22](index=22&type=chunk)[23](index=23&type=chunk) - Based on an initial analysis of recently announced tariffs, the company **does not expect any material cost impacts** in 2025[20](index=20&type=chunk) [Patent Portfolio](index=6&type=section&id=Patent%20portfolio) The company strengthened its IP by securing two key U.S. patents for its 212Pb generation and VMT-α-NET compound - A U.S. patent was allowed for the company's proprietary technology for generating 212Pb, with a term expiring in **August 2044**[24](index=24&type=chunk) - A U.S. patent was allowed for the VMT-α-NET compound, with a term expiring in **January 2041**[24](index=24&type=chunk) [First Quarter 2025 Financials](index=7&type=section&id=First%20Quarter%202025%20Financial%20Summary) [Financial Performance](index=7&type=section&id=Financial%20Performance) Q1 2025 net loss increased to $18.2 million, driven by higher R&D expenses, with a cash runway into late 2026 - Cash, cash equivalents, and short-term investments were approximately **$212 million** as of March 31, 2025, down from $227 million at year-end 2024[26](index=26&type=chunk) - In February 2025, the company sold 3,379,377 shares under its ATM agreement, raising gross proceeds of approximately **$10.2 million**[27](index=27&type=chunk) - The company's financial reporting now classifies the divested brachytherapy segment as **discontinued operations**[29](index=29&type=chunk) Q1 2025 vs. Q1 2024 Financial Results (Continuing Operations) | Financial Metric | Q1 2025 | Q1 2024 | Change | | :--- | :--- | :--- | :--- | | Grant Revenue | $0.3M | $0.3M | 0% | | R&D Expenses | $14.3M | $7.5M | +92% | | G&A Expenses | $7.8M | $5.9M | +33% | | Total Operating Expenses | $22.2M | $13.3M | +66% | | Net Loss | ($18.2M) | ($12.3M) | +48% | | Loss Per Share | ($0.25) | ($0.25) | 0% | [Financial Statements](index=12&type=section&id=Financial%20Statements) [Condensed Consolidated Balance Sheets](index=12&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased to $329.3 million as of March 31, 2025, primarily due to a reduction in cash Key Balance Sheet Items (in thousands) | Balance Sheet Item | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $44,406 | $61,580 | | Short-term investments | $167,296 | $165,336 | | **Total Assets** | **$329,349** | **$341,101** | | Total current liabilities | $12,679 | $18,230 | | **Total Liabilities** | **$44,704** | **$50,433** | | **Total Stockholders' Equity** | **$284,645** | **$290,668** | [Condensed Consolidated Statements of Operations](index=13&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Operating loss widened to $21.8 million for the quarter, driven by higher R&D expenses Consolidated Statement of Operations (in thousands) | Line Item | Three Months Ended Mar 31, 2025 | Three Months Ended Mar 31, 2024 | | :--- | :--- | :--- | | Grant revenue | $342 | $325 | | Research and development | $14,332 | $7,452 | | General and administrative | $7,842 | $5,878 | | **Operating loss** | **($21,832)** | **($13,005)** | | Total non-operating income, net | $3,655 | $1,180 | | **Net loss from continuing operations** | **($18,177)** | **($11,825)** | | **Net loss** | **($18,177)** | **($12,284)** | | **Basic and diluted loss per share** | **($0.25)** | **($0.25)** |

SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate and be available for one-on-one meetings with investors at the following upcoming investor conferences. Bank of America Global Healthcare ConferenceDate: Tuesday, May 13, 2025Format: Fireside ChatTime: 11:35 a.m. ...

SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced today that the first patient was treated with [Pb]PSV359 in a Phase 1/2a dose-finding trial to determine safety and preliminary anti-tumor activity of the radiopharmaceutical [Pb]PSV359 in patients with solid tumors that express fibroblast activation protein alpha (FAP-α). Pat ...

Core Insights - Perspective Therapeutics, Inc. announced that data on its [Pb]VMT-α-NET and [Pb]VMT01 programs have been accepted for presentation at the 2025 ASCO Annual Meeting, highlighting the company's ongoing commitment to advancing cancer treatments [1][2] Group 1: Company Overview - Perspective Therapeutics is a radiopharmaceutical development company focused on pioneering advanced treatments for various cancers using alpha-emitting isotopes [5] - The company employs a "theranostic" approach, combining targeted radiation therapy with imaging diagnostics to personalize treatment and optimize patient outcomes [5] Group 2: Clinical Programs - The [Pb]VMT-α-NET program targets SSTR2-positive neuroendocrine tumors and is currently in a multi-center, open-label dose escalation study [3] - The [Pb]VMT01 program is designed for MC1R-positive metastatic melanoma and is also undergoing a multi-center, open-label dose finding study [4] - Initial results from both programs have been presented at various oncology conferences, indicating ongoing research and development efforts [3][4] Group 3: Upcoming Presentations - The presentation of [Pb]VMT-α-NET will include data on dose-limiting toxicity and a one-year follow-up of participants, scheduled for May 30, 2025 [2] - The interim safety and efficacy data for [Pb]VMT01 in melanoma will be presented as a poster on June 2, 2025 [2]

Company Overview - Perspective Therapeutics, Inc. is a radiopharmaceutical company focused on pioneering advanced treatments for cancers throughout the body using proprietary technology that utilizes the alpha-emitting isotope 212Pb [2] - The company is developing complementary imaging diagnostics that incorporate the same targeting moieties, allowing for personalized treatment and optimized patient outcomes through a "theranostic" approach [2] Current Developments - The company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs are currently in Phase 1/2a imaging and therapy trials in the U.S. for treating metastatic melanoma and neuroendocrine tumors [3] - Perspective Therapeutics is expanding its regional network of drug product finishing facilities, supported by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations [3] Upcoming Events - The company will report its first quarter 2025 financial results and provide a business update on May 12, 2025, after the market closes [1]